Named on one round in the feed.
Since 2026-11-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Switchpoint Bio They provide a blood-based epigenomic platform for drug developers to understand how disease and treatment affect human biology. | Pre-seed Verified against 1 of 5 sources | $5.3M | 2026-11-10 | [ PART ] |
No one else named on these rounds.